Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry

References

• European Network for Understanding Mechanisms of Severe Asthma (ENFUMOSA). The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22(3):470–7
   Google Scholar
• Wenzel SE, Busse WW. National heart, lung, and blood institute’s severe asthma research program. Severe asthma: lessons from the severe asthma research program. J Allergy Clin Immunol 2007; 119(1):14–21.
   PubMed Web of Science ®Google Scholar
• Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, Calhoun WJ, Castro M, Chung KF, Clark MP, Dweik RA, Fitzpatrick AM, Gaston B, Hew M, Hussain I, Jarjour NN, Israel E, Levy BD, Murphy JR, Peters SP, Teague WG, Meyers DA, Busse WW, Wenzel SE. National heart, lung, blood institute’s severe asthma research program. Characterization of the severe asthma phenotype by the national heart, lung, and blood institute’s severe asthma research program. J Allergy Clin Immunol 2007; 119(2):405–413.
   PubMed Web of Science ®Google Scholar
• Miller MK, Johnson C, Miller DP, Deniz Y, Bleecker ER, Wenzel SE. Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol 2005; 116:990–S.
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D’Agostino RJr, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER. National heart, lung, and blood institute’s severe asthma research program. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010; 181(4):315–323.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60(3):309–316.
   PubMed Web of Science ®Google Scholar
• Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008; 102(1):71.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103(11):1633–1642.
   PubMed Web of Science ®Google Scholar
• Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009; 103(11):1725–1731.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, Caiaffa MF, Berra A, Schino P, Di Napoli PL, Maselli R, Pelaia G, Bucchioni E, Paggiaro PL, Macchia L. Italian real-life experience of omalizumab. Respir Med 2010; 104(10):1410–1416.
   PubMed Web of Science ®Google Scholar
• Vennera MD, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C; on behalf of the Spanish Registry. Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry-Some New Approaches. J Asthma 2012; 49(4):416–22.
   Google Scholar
• GEMA. 2009. Guia Española para el manejo del asma. Editorial Luzan 5. Madrid. Available at: www.gemasma.com. Accessed March 20, 2012.
   Google Scholar
• GINA. 2006. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO workshop report updated December 2011. Available at: http://www.ginasthma.com. Accessed March 20, 2012.
   Google Scholar
• Vega JM, Badia X, Badiola C, López-Viña A, Olaguíbel JM, Picado C, Sastre J, Dal-Ré R; Covalair Investigator  Group. Validation of the Spanish version of the Asthma Control Test (ACT). J Asthma 2007; 44(10):867–72.
   Google Scholar
• Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir Med. 2009; 103(8):1098–113.
   Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, Leo J, Peckitt C, Maykut R, Peachey G. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011; 66(5): 671–8.
   Google Scholar
• Van den Berge M, Pauw RG, de Monchy JG, van Minnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 2011; 139(1):190–193.
   PubMed Web of Science ®Google Scholar
• Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol 2011; 7(1):9.
   Google Scholar
• Sugino Y, Sanda R, Takagi Y, Kato M, Ohta A, Okumura J, Nagai H. A case of severe asthma responsive to omalizumab treatment despite a low serum IgE level and lack of sensitized allergens. Arerugi 2010; 59(11):1572–9.
   Google Scholar
• Humbert M, Durham SR, Ying S, Kimmit P, Barkans J, Assoufi B, Pfister R, Menz G, Robinson DS, Kay AB, Corrigan CJ. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and non-atopic asthma: evidence against “intrinsic” asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996; 154:1497–04.15.
   Google Scholar
• Humbert M, Durham SR, Kimmit P, Powell N, Assoufi B, Pfister R, Menz G, Kay AB, Corrigan CJ. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and non-atopic subjects with asthma. J Allergy Clin Immunol 1997; 99:657–65.
   PubMed Web of Science ®Google Scholar
• Ying S, Humbert M, Meng Q, Pfister R, Menz G, Gould HJ, Kay AB, Durham SR. Local expression of e germline gene transcripts and RNA for the e heavy chain of IgE in the bronchial mucosa in atopic and non-atopic asthma. J Allergy Clin Immunol 2001; 107:686–92.
   Google Scholar
• Humbert M, Grant JA, Taborda-Barata L, Durham SR, Pfister R, Menz G, Barkans J, Ying S, Kay AB. High-affinity IgE receptor (FceRI)-bearing cells in bronchial biopsies from atopic and non-atopic asthma. Am J Respir Crit Care Med 1996; 153:1931–7.
   Google Scholar
• Takhar P, Corrigan CJ, Smurthwaite L, O’Connor BJ, Durham SR, Lee TH, Gould HJ. Class switch recombination to IgE in the bronchial mucosa of atopic and non-atopic patients with asthma. J Allergy Clin Immunol 2007; 119(1):213–218.
   PubMed Web of Science ®Google Scholar
• Bhat KD, Calhoun WJ. Omalizumab in asthma: is the therapeutic window too small?. Chest 2011; 139(1):8–10.
   PubMedGoogle Scholar
• Pearlman AN, Chandra RK, Chang D, Conley DB, Tripathi-Peters A, Grammer LC, Schleimer RT, Kern RC. Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. Am J Rhinol Allergy 2009; 23:145–148.
   PubMed Web of Science ®Google Scholar
• Bachert C, Claeys SE, Tomassen P, van Zele T, Zhang N. Rhinosinusitis and asthma: a link for asthma severity. Curr Allergy Asthma Rep 2010; 10:194–201.
   PubMed Web of Science ®Google Scholar
• Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L. TENOR Study Group. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970–975.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Kelley JM, Boyd IO, Dutile S, Marigowda G, Kirsch I, Israel E, Kaptchuk TJ. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med. 2011; 365(2):119–26.
   Google Scholar
• Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma 2012; 49(2):144–52.
   Google Scholar
• Barbee R, Lebowitz M, Thompson H, Burrows B. Immediate skin-test reactivity in a general population sample. Ann Intern Med 1976; 84:129–133.
   PubMed Web of Science ®Google Scholar
• Tschopp JM, Sistek D, Schindler C, Leuenberger P, Perruchoud AP, Wuthrich B, Brutsche M, Zellweger JP, Karrer W, Brandli O. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the Sapaldia Study. Swiss study on air pollution and lung diseases in adults. Allergy 1998; 53:608–613.
   PubMed Web of Science ®Google Scholar